3-chloropropionamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-Chloropropionamide, also known as β-chloropropionamide, is an organic compound with the formula ClCH2CH2CONH2. It is a colorless solid. 3-chloropropionamide is a versatile synthetic intermediate used in the production of various chemicals and pharmaceuticals. It is also a potential building block for polymers and other functional materials. Research on 3-chloropropionamide primarily focuses on its synthesis, reactivity, and applications. Its biological activity, particularly as a potential antimicrobial or herbicide agent, is also being explored. Studies on 3-chloropropionamide are motivated by its potential as a valuable chemical intermediate and the need to understand its environmental impact and potential biological effects.'

3-chloropropionamide: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	79982
CHEMBL ID	171266
SCHEMBL ID	120934
SCHEMBL ID	10439099
MeSH ID	M0403467

Synonyms (34)

Synonym
ai3-21062
unii-1a4dt52kjv
einecs 227-542-2
1a4dt52kjv ,
nsc 401789
3-chloropropionamide
5875-24-1
propanamide, 3-chloro-
nsc-401789
nsc401789
3-chloropropionamide, 98%
AKOS000141502
3-chloropropanamide
3-chloro-propionamide
CHEMBL171266 ,
jqdxzjyausvhdh-uhfffaoysa-
inchi=1/c3h6clno/c4-2-1-3(5)6/h1-2h2,(h2,5,6)
EN300-53733
BBL011453
STL146565
FT-0635892
S12033
SCHEMBL120934
3-chloro-propanamide
SCHEMBL10439099
3-chloropropanamide #
mfcd00008040
AS-54557
CS-0204808
bdbm50224816
DTXSID70974269
3-chloropropanimidic acid
.beta.-chloropropionamide
SY101532

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Alcohol dehydrogenase E chain	Equus caballus (horse)	Ki	5,300.0000	0.1412	2.8927	8.7000	AID33720
Alcohol dehydrogenase S chain	Equus caballus (horse)	Ki	5,300.0000	0.1412	2.8927	8.7000	AID33720
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay ID	Title	Year	Journal	Article
AID183376	In vivo inhibition of ethanol metabolism following 1 mMol/Kg p.o.	1983	Journal of medicinal chemistry, Jun, Volume: 26, Issue:6	Inhibition by carboxamides and sulfoxides of liver alcohol dehydrogenase and ethanol metabolism.
AID33720	In vitro inhibition against horse liver alcohol dehydrogenase	1983	Journal of medicinal chemistry, Jun, Volume: 26, Issue:6	Inhibition by carboxamides and sulfoxides of liver alcohol dehydrogenase and ethanol metabolism.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	12 (92.31)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (7.69)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	11.50 (24.57)
Research Supply Index	2.64 (2.92)
Research Growth Index	4.14 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (11.50)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	13 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
beta-alanine [no description available]	2	1	amino acid zwitterion; beta-amino acid	agonist; fundamental metabolite; human metabolite; inhibitor; neurotransmitter
tetramethylene sulfoxide [no description available]	1.96	1	tetrahydrothiophenes
diethyl sulfoxide [no description available]	1.96	1
beclamide beclamide: structure	2.34	2	benzenes
isovaleric acid isovaleric acid: structure. isovaleric acid : A C5, branched-chain saturated fatty acid.	2	1	branched-chain saturated fatty acid; methylbutyric acid; short-chain fatty acid	mammalian metabolite; plant metabolite
butyramide butanamide : A monocarboxylic acid amide obtained by formal condensation of butanoic acid and ammonia.	7	1	butanamides; primary fatty amide
isovaleramide isovaleramide: inhibits liver alcohol dehydrogenases	7.38	2
2-piperidone 2-piperidone: structure given in first source. piperidin-2-one : A delta-lactam that is piperidine which is substituted by an oxo group at position 2.	1.96	1	delta-lactam; piperidones	EC 1.2.1.88 (L-glutamate gamma-semialdehyde dehydrogenase) inhibitor
cyclohexamethylene carbamide cyclohexamethylene carbamide: structure	1.96	1
methyl phenyl sulfoxide (methylsulfinyl)benzene : A sulfoxide resulting from the formal oxidation of the sulfur atom of thioanisole.	1.96	1	benzenes; sulfoxide
acetylglucosamine Acetylglucosamine: The N-acetyl derivative of glucosamine.. N-acetyl-beta-D-glucosamine : An N-acetyl-D-glucosamine having beta-configuration at the anomeric centre.	2	1	N-acetyl-D-glucosamine	epitope
isobutyramide [no description available]	1.96	1	carboximidic acid
cyclopropanecarboxamide cyclopropylcarboxamide : Carboxamides RC(=O)NR'R'' where R is a cyclopropyl group.	1.96	1	cyclopropylcarboxamide
n-acetylglucosaminylasparagine N-acetylglucosaminylasparagine: RN given refers to parent cpd; presence in urine characteristic of aspartylglucosaminuria; structure. N(4)-(beta-N-acetyl-D-glucosaminyl)-L-asparagine : An N(4)-glycosyl-L-asparagine having (beta-N-acetyl-D-glucosaminyl as the glycosyl component.	2	1	amino acid zwitterion; glucosaminylamine; N(4)-glycosyl-L-asparagine
beta-alanine amide beta-alanine amide: structure. beta-alaninamide : An amino acid amide compound consisting of propionamide having a 3-amino substituent.	2	1	amino acid amide
thiosemicarbazide thiosemicarbazide: glutamate decarboxylase antagonist; structure given in first source. hydrazinecarbothioamide : A member of the class of thioureas that is thiourea in which a hydrogen of one of the amino groups is replaced by an amino group.	1.96	1	hydrazines; thiocarboxamide; thioureas
thiourea Thiourea: A photographic fixative used also in the manufacture of resins. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance may reasonably be anticipated to be a carcinogen (Merck Index, 9th ed). Many of its derivatives are ANTITHYROID AGENTS and/or FREE RADICAL SCAVENGERS.. thiourea : The simplest member of the thiourea class, consisting of urea with the oxygen atom substituted by sulfur.	1.96	1	one-carbon compound; thioureas; ureas	antioxidant; chromophore

Condition	Relationship Strength	Studies
Aura [description not available]	2.62	3
Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)	7.62	3
Circulatory Collapse [description not available]	1.93	1
Shock A pathological condition manifested by failure to perfuse or oxygenate vital organs.	1.93	1
Behavior Disorders [description not available]	1.94	1
Child Behavior Disorders Disturbances considered to be pathological based on age and stage appropriateness, e.g., conduct disturbances and anaclitic depression. This concept does not include psychoneuroses, psychoses, or personality disorders with fixed patterns.	1.94	1
Callous-Unemotional Traits [description not available]	1.94	1
Mental Disorders Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of thought, feeling, and behavior producing either distress or impairment of function.	1.94	1
Conduct Disorder A repetitive and persistent pattern of behavior in which the basic rights of others or major age-appropriate societal norms or rules are violated. These behaviors include aggressive conduct that causes or threatens physical harm to other people or animals, nonaggressive conduct that causes property loss or damage, deceitfulness or theft, and serious violations of rules. The onset is before age 18. (From DSM-IV, 1994)	1.94	1
Absence Seizure [description not available]	1.93	1
Seizures Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.	1.93	1

chemdatabank.com